A Phase 1 interventional study of KK2260 and KK2260 in Advanced or Metastatic Solid Tumors, sponsored by Kyowa Kirin Co., Ltd.. Recruiting at 14 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Kyowa Kirin Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.
Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
\<Common Inclusion Criteria for Part 1a, Part 1b, and Part 2
\<Additional Inclusion Criteria for Part 1a
1) Patients with diagnosed advanced or solid tumors.
\<Additional Inclusion Criteria for Part 1b
\<Additional Inclusion Criteria for Part 2a
\<Additional Inclusion Criteria for Part 2b
Exclusion Criteria:
\<Common Exclusion Criteria to Part 1 and Part 2>
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KK2260
Drug: KK2260
KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
Dose-limiting toxicity (Only in Part 1a)
Time frame: During the first cycle (1 Cycle = 28 days)
Adverse Events
Time frame: Through study completion, an average of 1 year
Changes in Laboratory Testing Values (Red blood cell count)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Hemoglobin concentration)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Hematocrit)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Reticulocyte)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Mean corpuscular volume)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Mean corpuscular hemoglobin)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Mean corpuscular hemoglobin concentration)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (White blood cell count)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Differential white blood cells (basophils, eosinophils, lymphocytes, monocytes, neutrophils))
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Platelet count)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Total protein)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Albumin)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Alkaline phosphatase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Alanine aminotransferase/Aspartate aminotransferase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Total bilirubin/Direct bilirubin)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Blood urea nitrogen)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Calcium/Corrected Calcium)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Chloride)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Potassium)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Sodium)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Magnesium)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Serum iron)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Ferritin)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Total iron binding capacity)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Unsaturated iron binding capacity)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Serum creatinine)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Creatinine clearance (Cockcroft-Gault formula))
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Lactate dehydrogenase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Blood glucose)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Uric acid)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Lipase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Amylase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (C-reactive protein)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Gamma-glutamyl transpeptidase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Triglycerides)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Cholesterol)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Creatine phosphokinase)
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Coagulation test)
Prothrombin time international normalized ratio and Activated partial thromboplastin time
Time frame: Every week through study completion, an average of 1 year
Changes in Laboratory Testing Values (Hepatitis B virus DNA, if needed)
Time frame: Every 2 cycle through study completion, an average of 1 year (1 Cycle = 28 days)
Changes in Body temperature (degree Celsius)
Time frame: Every week through study completion, an average of 1 year
Changes in Systolic and Diastolic Blood Pressure (mmHg)
Time frame: Every week through study completion, an average of 1 year
Changes in SpO2 (%)
Time frame: Every week through study completion, an average of 1 year
Changes in Electrocardiogram parameters (Heart rate, PR interval, QRS interval, QT interval, and QTc intervals)
The resting Heart rate, PR interval, QRS interval, QT interval, and QTc intervals will be recorded. Any abnormalities in ECG will be specified and documented as clinically significant or not clinically significant.
Time frame: Every week through study completion, an average of 1 year
Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS) (The score should be 0 to 4, and the lower is the better.)
Time frame: Every week through study completion, an average of 1 year
Serum concentration levels of KK2260
Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)
Maximum Plasma Concentration (Cmax)
Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)
Area Under the blood concentration-time Curve (AUC)
Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)
Anti-drug antibody
Time frame: Pre-dose and post-dose at multiple timepoints for each cycle during the intervention (each cycle is 28 days)
Overall Response Rate (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Disease Control Rate (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Duration of Response (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Progression-Free Survival (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Overall Survival (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Time to Response (in Part 1b/2)
Time frame: During the treatment and every 12 weeks after study treatment completion (approximately up to 1 year)
Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Oct 2029, 71 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.